Every material Form 8-K InfuSystem Holdings, Inc has filed with the SEC since October 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
InfuSystem furnished an investor presentation dated November 9, 2026, under Regulation FD. It shows higher profit for the third quarter and nine months of 2026 and gives estimates for 2026 proforma revenue growth of 6%-8% and a low-to-mid 20% margin. For shareholders, the figures show continued profit growth, though the estimates are company projections and not guaranteed results.
GAAP net income was $3.2 million for the quarter ended September 30, 2026, versus $2.3 million a year earlier.
Nine-month GAAP net income was $7.4 million in 2026, versus $4.6 million in 2025; nine-month adjusted EBITDA was $24.3 million versus $22.7 million.
Estimates as of September 30, 2026 call for 2026 proforma revenue growth of 6%-8%.
Trailing twelve-month net revenue was $144.4 million and liquidity was $64.1 million as of September 30, 2026; net leverage ratio was 0.32x.
InfuSystem reported third-quarter 2026 net revenue of $37.6 million, up 3.0% from the prior year, and net income of $3.2 million, or $0.15 per diluted share, versus $2.3 million, or $0.11, a year earlier. The company reaffirmed its full-year 2026 guidance, which reflects a previously announced GE Healthcare contract restructuring that lowered reported revenue.
Net revenue $37.6 million, up 3.0% from $36.5 million; Patient Services up 15%, Device Solutions down 17%
Net income $3.2 million, or $0.15 per diluted share, versus $2.3 million, or $0.11, in Q3 2025
Adjusted EBITDA (non-GAAP) $9.4 million, up 12.5%, with a margin of 24.9%
Full-year 2026 guidance reaffirmed: pro-forma revenue growth of 6% to 8% and Adjusted EBITDA margin in the low-to-mid 20% range; conference call November 10, 2026 at 9:00 a.m. Eastern Time
InfuSystem Holdings postponed the release of its third quarter 2026 financial results, which had been scheduled for November 3, 2026, saying it needs more time to complete its quarter-end reporting process. The Company, its Audit Committee and its independent auditor are evaluating whether ERP system implementation costs should be capitalized and amortized instead of expensed as incurred, and any adjustment would be non-cash and would not affect revenue or cash balances.
Third quarter 2026 results, originally due November 3, 2026, postponed with no new date given; the Company will announce one as soon as practicable
Under review: whether ERP implementation costs should be capitalized and amortized over the remaining three-year software subscription term
Costs totaling $4.2 million were expensed as incurred from July 1, 2024 to March 1, 2026, when the ERP system went live
Any accounting adjustment would be non-cash and would not affect revenue or cash balances
InfuSystem Holdings announced it will release its third quarter 2026 financial results before the market opens on Tuesday, November 3, 2026, and hold a conference call that morning at 9:00 a.m. Eastern Time. The filing is a scheduling notice and contains no financial results, so it does not show how the quarter performed.
Third quarter 2026 results to be released before market open on Tuesday, November 3, 2026
Investor conference call set for 9:00 a.m. Eastern Time on November 3, 2026
Replay available through Wednesday, February 3, 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every InfuSystem Holdings, Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →